Meningitis
Conditions
Keywords
Group ACYW135 Meningococcal Polysaccharide Vaccine
Brief summary
The clinical trial was designed to evaluate the safety against Group ACYW135 Meningococcal Polysaccharide Vaccine of Hualan administered on subjects 2 years of age and older.
Detailed description
Complying with requirements of the approval letter of clinical trial issued by SFDA (Approval Letter No.: 2006L01017), Hualan conducted phase I clinical trial of Group ACYW135 Meningococcal Polysaccharide Vaccine. The safety end points were the presence of any systemic, local and adverse reaction.
Interventions
60 subjects were divided into three groups (20 subjects each group), adult (16\ 30 years of age), early youth (7\ 15 years of age) and children (2\ 6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
Sponsors
Hualan Biological Engineering, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy permanent residence 2 years of age and older, the subjects (or their guardians) are able to understand and sign the informed consent; * Healthy male or female by oral history, physical examination and clinical judgment and who complies with vaccination of this product; * Be able to comply with the requirements of clinical trial protocol and immunogenicity examination; * Have no history of vaccination within the past 3 months and vaccination with other products within the last 2 weeks; * Axillary temperature ≤37.0℃.
Exclusion criteria
* Any acute disease, such as: tumor, autoimmunity disease, progressive atherosclerotic disease or diabetes with complication, chronic obstructive pulmonary disease need oxygen uptake, acute or progressive hepatopathy or nephropathy, congestive heart-failure, etc.; * Allergic to vaccines or drugs (history of allergy to any vaccine in the past); * History of neurologic symptom or signs; * Known or suspected (or high risk) impaired or abnormal immune function, e.g.: receive immunosuppressant or immunopotentiator therapy, take immunoglobulin or blood product or plasma extract (except the gastrointestinal tract) within the past 3 months, HIV infection or related disease, etc.; * History of meningitis infection or vaccination of meningococcal vaccine within the past 3 months; * History of receiving other vaccines or immunoglobulin injection or any research drugs; * Any acute disease needing application of antibiotics or anti-virus treatment in the whole body within the past 1 week; * History of fever within the past 3 days (axillary temperature ≥38.0℃); * Participating in another clinical trial; * History of allergy, eclampsia, epilepsy, encephalopathy and mental disease or family disease; * Thrombopenia or other coagulopathy that may cause contraindication to intramuscular injection; * Acute chronic disease (such as Down syndrome, diabetes, sickle cell anemia or neurologic disease, Guillain-Barre Syndrome); * Known or suspected diseases, including: respiratory system disease, acute infection or active stage of chronic disease, SBAV infection of children or mothers, cardiovascular disease, acute hypertension, cancer treatment, skin disease, etc.; * Pregnancy; * Any condition that, in the judgment of investigator, may affect trial assessment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety | Day 28 after vaccination | All systemic and local adverse reactions and related adverse events on day 28 after the vaccination |
Outcome results
None listed